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 To you; 
the past, current or future patient, 
my partner in care 
and my teacher of life. 
“Measure what is measurable, 
and make measurable what is not so” 
– Galileo Galilei
“A great building must begin with the unmeasurable, 
must go through measurable means when it is being designed 
and in the end must be unmeasurable” 
– Louis Kahn
“I don’t follow orders, 
and I don’t lie about what I do to manage my condition; 
what I do I do for myself” 
– Dominick L Frosch
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 ABSTRACT 
Background. Value-based health care (VBHC), a strategic framework launched in 2006, 
suggests restructuring health care to maximize health outcomes in relation to societal costs. 
The framework builds upon a tradition of outcome assessment in clinical work and health 
economic evaluation. In suggesting maximization of outcomes in relation to costs, the 
framework makes assumptions about what constitute a valuable outcome to persons with a 
disease, and how this should be operationalized. The framework, for example, assumes: 
(A) only outcomes matter to patients; (B) outcomes that matter to patients are separable into 
three categories: health status achieved, time to health status achieved, and sustainability of 
health; and (C) standardized instruments are preferable when operationalizing a certain 
outcome. Critique has been raised towards VBHC as being ill adapted to the chronic care 
setting. 
Aim. The aim of this thesis is to assess assumptions (A-C) of VBHC in a chronic care setting. 
Methods. This thesis uses a mixed-methods approach. First, the current understanding and 
application of VBHC in the research literature is assessed using literature citation data. 
Secondly, empirical consequences of the assumptions (A-C) are assessed in the setting of 
rheumatology, using a randomized controlled trial (A) and semi-structured interviews (B-C). 
The research participants had rheumatoid arthritis (RA). 
Findings. This thesis shows that the literature has not assessed assumptions of VBHC 
empirically; non-outcomes can have intrinsic value to persons with RA (A); outcomes not 
found in the outcome categories can have intrinsic value to persons with RA (B); and a 
common functional measurement in rheumatology, Stanford’s Health Assessment 
Questionnaire-Disability Index, is not aligned with the perspective of persons with RA (C). 
Discussion. The framework assumptions did not find support in the setting of rheumatology. 
This thesis does not address settings other than rheumatology and not all aspects of the 
assumptions. However, the findings show that the assumptions are not universally applicable. 
There are several possible reasons for the disagreement between the assumptions and the 
findings. The most reasonable is that VBHC addresses care from the perspective of the 
provider. Although the needs and challenges of the provider might be fully addressed by 
VBHC, the perspective of patients with RA is not. The disagreement between the 
assumptions and the findings, in combination with the lack of assessment in the scientific 
literature, raises the question whether VBHC is a scientific or a non-scientific framework. 
Conclusion. The thesis shows limitations of VBHC in one specific setting, using data from 
persons with RA. Those specific limitations can most likely be avoided if VBHC were 
adjusted and implemented in patient-professional partnership. 
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 PREFACE 
To sustainably change how the world is lived, one must start with the world as it is. My 
scientific endeavor began out of this necessity—to maximize clarity of thought and 
correspondence of my mental models to this (perceived) external reality. I started in 
mathematics but my inner norms pushed me into medicine. There, my passion grew from the 
idea of improving life for persons who sought my advice as a physician, and science became 
the method simply because it is the best known way of tackling challenges. Although 
working as a physician can be rewarding, interesting, and meaningful, the deed rapidly cools 
as you gain a system perspective of health and suffering.  
When I summarized the achievements—six years after I planned the first study in this 
thesis—I reconciled with the idea that science has indefinite room for improvement. For me, 
becoming a researcher has been about accepting the limitations of research design and 
conclusions, and as such learning to smile at the endless iterations. The challenge was always 
to know when a study is—as the management consultants would phrase it—“good enough.” 
Enjoy the reading, insights, and failures. I did. 
 
David Ebbevi 
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 1 BACKGROUND 
1.1 VALUE-BASED HEALTH CARE 
In the past century, many attempts have been made to improve care while containing societal 
costs (1). Increased life span, technological improvement, and better-informed patients have 
increased the demand for care (2, 3). However, despite increased spending, health care 
systems are struggling to cover the increased demand (1). 
Attempts to improve care while containing costs have resulted in an explosion of approaches 
(e.g., (1, 3-5)) and strategic frameworks, but no consensus on what it means to “improve” 
care. One of these strategies has been termed value-based health care (VBHC). Porter, its 
main proponent, outlined VBHC in a series of publications as a strategy for providers (4, 6-
12). The main principle of VBHC is that the purpose of health care is to maximize results 
(outcomes) in relation to the money spent.  
This thesis compares underlying assumptions of outcome measurements in VBHC with the 
perspective of RA patients. Other aspects of VBHC, such as costs, will not be addressed.  
The many frameworks for improving care share similar traits. Before diving deeper into 
VBHC and its specific similarities to other frameworks, the next section (1.2) addresses a 
concept useful in understanding how such similarities arise: pseudoinnovation. 
1.2 PSEUDOINNOVATION 
The many views on what it means to improve care could give the impression that there is an 
infinity of ways to manage care. However, Bohmer suggested the tools available to health 
care managers are in fact limited to managing through values, resources, outcomes, 
processes, and decision systems (1). This limited amount of tools would imply that all 
strategic frameworks are restricted to different configurations of those tools. In addition, 
many specific quality-improvement tools (e.g., Lean (13) or Total Quality Management, 
TQM (14)) are conceptually similar to each other (15)). 
Despite the limited tools available and the conceptual similarity among the specific tools, 
new quality-improvement tools are often launched as different from predecessors despite 
their strikingly likenesses. The phenomena giving rise to the conceptual similarity between 
new and existing management ideas has been termed the fashion perspective on innovation 
(16) or pseudoinnovation (15). The new ideas are “pumped” for three to five years before 
they are “dumped” to the benefit of another management idea (15). Generally the upswing is 
characterized by emotional and unreasoned discourse, whereas the downswing is 
characterized by qualified and unemotional discourse (17). Some studies have argued that this 
cycle of management ideas is driven by the knowledge producer (i.e., the framework creator 
(15, 18)), whereas others argued that the cycle happens in interaction with the managers who 
implement the idea (19). Pseudoinnovation is reinforced by competition among knowledge 
producers to predict and use trends in management (20). To launch a theory as new and 
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different gives the appearance that the knowledge producer stays at the forefront of 
management development. Abrahamson suggests that scholars should assess the management 
innovation process critically and intervene against pseudoinnovation to make management 
innovation more useful (20).  
1.3 VALUE FRAMEWORKS IN HEALTH CARE 
Different stakeholders define the term value differently and in different contexts (21). The 
focus of this thesis, VBHC (first proposed by Porter and Teisberg in 2006 (4)), is only one of 
recent developments. Other value interpretations, such as triple aim (22), triple value care 
(23), value compass (24), value of co-creation (25(p32)), and the vast philosophical literature 
on value theory have been intentionally omitted from this thesis to retain its focus and clarity. 
The following section (1.3.1) briefly covers a method used to compare value in health 
economic evaluation before describing VBHC.  
1.3.1 Cost-effectiveness analysis to quantify value 
Scarce health care resources force policymakers and professionals to make trade-offs in 
resource allocation. Such trade-offs can be structurally assessed through health economic 
evaluations, which focus on relating costs to results such as alternative costs, number of 
procedures, lifespan, or quality of life. Cost-effectiveness is defined as the cost of a specific 
outcome; that is, a specific program’s cost in relation to its natural units, such as the cost to 
find one case of a disease or cost per blood pressure improvement (26): 
𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑐𝑐𝑐𝑐𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑐𝑐𝑐𝑐 = 𝑒𝑒𝑒𝑒𝑐𝑐𝑖𝑖𝑒𝑒𝑖𝑖𝑒𝑒𝑒𝑒𝑐𝑐𝑖𝑖𝑖𝑖 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐
𝑐𝑐𝑜𝑜𝑐𝑐𝑐𝑐𝑐𝑐𝑖𝑖𝑒𝑒
1.3.1.1 Outcomes in history and present-day health care 
The idea of measuring health care outcomes predates health economic evaluations and its 
applications go beyond economic appraisal. Codman first proposed outcome measurement in 
the beginning of the 20th century. He called it the end results idea and described it as a 
practice wherein “every hospital should trace each patient with the object of ascertaining 
whether maximum benefit has been obtained and to find out if not, why not.…The results 
shall be constantly analyzed and possible methods of improvement constantly considered” 
(27).  
These “end results” came to be known as outcomes and gained increased attention following 
the work of Donabedian (28). The practice was first implemented in clinical settings during 
the 1980s (1) and later garnered even greater focus (29, 30). The interest led to developing 
specific models for separating outcomes (e.g., the ECHO model (31) separates outcomes into 
economic, clinical, and patient-reported categories). Outcomes can encompass any health-
related result of health care, such as mortality, functional ability, or pain. As an interesting 
2 
 side note, a study reported that breast cancer patients preferred the terms medical results or 
what my life will be like over the term outcomes (32). 
This measurement trend caught momentum in rheumatology (33), most notably in the 
outcome model published by J. F. Fries in 1983 (34) and shown in Figure 1. Fries’ model 
postulated important outcomes in five areas. He proposed measuring the displayed outcomes 
over time with the goal to minimize the area under the outcome curve. 
 
 
 
Figure 1. Outcomes in Rheumatoid Arthritis As described by J. F. Fries in 1983. Reproduced 
with permission from J. F. Fries, The assessment of disability: from first to future principles. 
Rheumatology, 1983;22(suppl 1):48-58(34). Copyright Oxford University Press. 
 
1.3.2 VBHC: What is it? 
Value-based health care has been marketed as “the strategy that will fix health care” (10). 
This overarching strategy of VBHC can be summarized in three principles (6).  
First, the goal of health care is value for patients. Health care should focus on outcomes—
what matters to patients—and not on the process or the structure of health care facilities. It is 
argued that every meaningful improvement to the process of health care will be reflected by a 
measurable improvement in patient outcome (4). This outlook that processes are only 
instruments used to improve outcomes runs at odds with some researchers’ views. For 
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example, Donabedian argued that care cannot focus only on improving outcomes because 
many outcome responses are delayed or difficult to collect (35).  
To highlight the importance of outcomes, Porter defined value as outcome in relation to costs 
(4): 
𝑉𝑉𝑖𝑖𝑖𝑖𝑜𝑜𝑒𝑒 = 𝑂𝑂𝑜𝑜𝑐𝑐𝑐𝑐𝑐𝑐𝑖𝑖𝑒𝑒
𝐶𝐶𝑐𝑐𝑐𝑐𝑐𝑐
Porter’s equation is similar to an inverted version of the health economic evaluation equation 
(section 1.3.1), but the primary purpose of porters equation is not economic appraisal. The 
ratio outcome/cost is not to be taken literally or calculated into a single number. In fact, the 
outcomes are seen as multidimensional. Consequently, Porter’s equation illustrates the 
relationship between outcomes and costs with the idea that to maximize value, providers 
should improve outcomes while maintaining or decreasing costs. In addition, Porter asserted 
that because the goal of value aligns with what is important to patients, it would feel more 
meaningful to providers to work towards value than towards other potential goals. 
Professionals would therefore be motivated more by potential value improvement than by 
other incentives (12).  
Second, care is organized over medical conditions and full care cycles. Here, medical 
condition is defined as a patient’s state best treated in an integrated manner (4). In practice, 
this means a medical condition is either a diagnosis including common complications or, as 
in primary and preventive care, a segment of conditions with similar complexity (11). For 
each medical condition, instruments should be selected to measure outcome. In VBHC, 
measurements must be broad in the sense that they should include all parts of care for a 
certain medical condition. Thus, improvement of care at early stages affects the 
measurements even if the effect of the improvement is only seen at later stages. Conversely, 
the measurements need to be narrow in the sense that no measurement should include patients 
with different medical conditions (4) because outcome and cost are assumed to differ 
between medical conditions. 
Third, costs and outcomes have to be quantitatively measured to assess value. (For a detailed 
description on how to measure costs, see (36).) Outcomes are here distinguished from other 
potential measurements, such as process-, structural-, clinical-, or patient-reported experience 
measurements. This thesis refers to such measurements as non-outcomes. (Note that patient 
satisfaction with care is included in Donabedian’s definition of outcomes(35) but excluded 
here). Details on how to measure outcomes in accordance with VBHC are covered in the next 
section (1.3.2.1). 
1.3.2.1 Three-tier model for separating outcomes 
To support choice of outcome measurements in VBHC, Porter developed a separate model 
(Figure 2). The model includes three dimensions (tiers) of outcomes (9): health status 
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 achieved or retained, process of recovery, and sustainability of health. Each tier is subdivided 
into two levels. These categories are not novel. They were applied in evaluations before 
Porter’s publication of the three-tier model (e.g., for migraine (37)). However, Porter made a 
number of claims in connection with publishing the model. Specifically, he assumed all 
relevant outcomes fit into the categories; there is a hierarchical relationship between the tiers 
where tier one is most important; and if one measurement is chosen per level, then 
improvement in those outcomes will invariably decrease costs (38). The specific examples in 
Figure 2 and Porter’s other applications are not meant to be exhaustive. They demonstrate 
only the categories used to separate outcomes. The arrows indicate causal connections among 
outcomes. However, it is unclear how this model would apply to chronic diseases (39). Porter 
proposed an adaptation to the setting of chronic, primary, and preventive care (11) wherein 
the levels would be preserved but their interpretation expanded.  
 
 
Figure 2. Three-Tier Model for Outcomes. Reproduced with permission from M. E. Porter, 
What is value in health care? New England Journal of Medicine, 2010;363(26):2477-81. 
Copyright Massachusetts Medical Society. 
Disutility of care or treatment process 
(e.g., diagnostic errors, ineffective care, 
treatment-related discomfort, compli- 
cations, adverse effects) 
Sustainability of health or recovery 
and nature of recurrences 
Long-term consequences of therapy 
(e.g., care-induced illnesses) 
Survival 
Degree of health or recovery 
Time to recovery and time to return 
to normal activities 
Tier 1 
Health status 
achieved 
or retained 
Tier 2 
Process 
of recovery 
Tier 3 
Sustainability 
of health 
Recurrences 
Care-induced 
illnesses 
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Table 1 this expanded interpretation of the three-tier model for chronic care settings. When 
choosing specific instruments to measure outcomes, Porter preferred standardized scales 
(e.g., 36-Item Short-Form Health Survey (SF-36), Western Ontario and McMaster 
Universities Osteoarthritis Index, EuroQol Group 5-Dimension Self-Report Questionnaire, 
Beck Depression Index) when available (38). A few publications about VBHC also 
mentioned a need to create indicators (4(p128), 12) and incentives to do so (40(p96)), but did 
not further develop the argument.  
Table 1. Interpretation of the Three-Tier Model in the Chronic Care Setting 
Level Subcategories suggested by Porter (9) and Porter et al. (11) 
Survival Mortality (1-yr, 3-yr, 5-yr, longer) 
Degree of recovery or health Physical and mental functional status 
Control of chronic disease complications 
Pain level achieved 
Ability to return to work 
Time to recovery or to return to 
normal activities 
Time to treatment or definitive diagnosis 
Time to access specialist treatment for more complicated or 
urgent issues 
Time spent accessing treatment 
Workdays missed or time to return to work 
Disutility of care or treatment 
process 
Pain and anxiety before and during treatment 
Care complications 
Length of hospital stay 
Need for emergency department visits or hospitalizations 
Sustainability of recovery or 
health over time 
Maintenance of functional level 
Frequency of urgent care issues 
Acuity of chronic conditions and complications 
Ability to live independently 
Need for revision or reoperation 
Long-term consequences of 
therapy 
Long-term side effects or care induced illnesses 
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 1.3.2.2 Comparison of Fries’ and Porter’s outcome models 
Comparing Fries’ outcome model (Figure 1) to Porter’s (Figure 2), the similarities are 
striking. Fries separated outcomes in terms of discomfort and disability, whereas Porter 
distinguished between the health statuses achieved and sustained. In addition, Fries’ category 
Iatrogenic equals Porter’s categories of process disutility and long-term health. The specific 
content of these categories are the same. Further, both models recognize the importance of 
time but deal with it differently. Fries’ model measured time as the area under the outcomes 
curve, whereas Porter’s model measured it as separate data points (i.e., time to recovery). 
Thus, Fries’ model aggregated outcome and time into one number and, in doing so, assumed 
the outcome is a ratio scale. As such, Fries’ model more easily applies to chronic conditions 
that do not have clear endpoint towards which time can be measured. Further, Fries included 
costs as an outcome, but Porter kept outcome separate from the outcome model. Explicitly 
explaining this choice, Porter stated, “Treating cost as an outcome will only obscure value by 
confusing the process of care with the results of care” (41).  
Despite the models’ similarities, Porter made sparse reference to any earlier work on 
outcomes in his 2010 publication (9). Assuming Porter was unaware of Fries’ outcome 
model, this similarity could be seen as a sign of reliability (42) or investigator triangulation 
(43). That is, the fact that two researchers ended up with similar conclusions supports the idea 
that the models include outcomes non-patients believe are important to patients. Whether the 
models reflect outcomes patients themselves think are important is not known. 
1.3.2.3 VBHC substrategies to maximize value 
Clinical care determines only 20% of health outcomes (excluding genetics). The rest of the 
outcomes are determined by health behaviors (e.g., smoking and exercise), social and 
economic factors (e.g., education and income), and the physical environment (e.g.. air and 
water quality) (44). Initially, preventive care was a core part of VBHC (8), but later 
publications instead focused on clinical care delivery. Thus, when Porter et al. suggested six 
substrategies to maximize value, their suggestions concerned how to structure clinical care 
(10):  
1. Administratively (and preferably physically) organize care as integrated practice 
units with all resources necessary to treat a medical condition.  
2. Measure costs and outcomes, as introduced in the section above.  
3. Reimburse health care costs through bundled payments for care cycles. This strategy 
differs from paying per patient (global capitation) or per service (fee-for-service). 
Instead, bundled payments are allocated per patient and medical condition. (For more 
detailed discussion, see (45).) 
4. Integrate care delivery across separate facilities. This means providers who do not 
cover the full cycle of care should form partnerships with organizations and locations 
that cover the other parts of the cycle. 
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5. Expand services that deliver high value to cover greater geographical areas by
establishing satellite facilities that handle less complicated parts of the care cycle.
Preferably, health care professionals rotate among these locations.
6. Support the substrategies listed above through a health care information technology
platform.
The empirical data presented is limited to cases illustrating each separate substrategy. No case 
illustrates the combined effect of all substrategies. Therefore, the questions of whether the 
substrategies interact and would work as expected when put together remains unanswered. 
Porter asserted they are “mutually reinforcing” (10), but no study has demonstrated a 
combination of all the substrategies. 
1.3.2.4 Tactical and operational tools 
Although some specific tools may generally be better at achieving value than others (46), 
VBHC does not prescribe any particular operational tools. Therefore, providers applying 
VBHC must themselves decide what they should do to improve outcomes without increasing 
cost. These decisions include, for example, which processes to measure internally; how to 
manage clinical practice guidelines and human resources; selecting quality improvement 
tools such as Lean (13), TQM (14), or quality registers (47); and whether to include other 
approaches such as person-centered care (48). 
1.4 VBHC IN A CHRONIC CARE SETTING 
The chronic care setting constitutes a challenge when delivering care in general and value-
based care in particular. Chronic disease differs from acute episodes in its complexity, need 
for self-care, and importance of family support (49). Complexity makes it more difficult to 
standardize and execute care in an integrated fashion. Instead an iterative approach based on 
interaction between professionals and patients can be more suitable (1). Care is often 
fragmented and provided by many actors (50); thus, integrating chronic care requires 
substantial effort (51). This fragmentation encourages short-term goals (51) that could be at 
odds with the patient’s goal of long-term health (49). To support self-care, approaches such 
as person-centered care (48), education in self-management, or patient-formed networks to 
support or mentor each other (52) are applicable. 
In VBHC, outcomes are defined in a way that requires an endpoint at which the measurement 
is performed. Thus, for example, it is not obvious when to measure health status achieved for 
persons with chronic diseases. Studies have raised criticism concerning how to apply VBHC 
to unpredictable health conditions or persons with multiple active comorbidities (53), and 
specifically how to apply it to chronic and palliative care (49). The critiques primarily argued 
that patients with chronic conditions might value more than sustainability (such as family 
support), and thus it would be better to focus on the whole trajectory of illness than to 
emphasize health status achieved (49). Further, questions about how to bridge VBHC with 
patient-centered care have been raised elsewhere (54, 55). 
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 1.5 VBHC CRITIQUE AND ASSUMPTIONS 
The assumptions of VBHC were not addressed in the theoretical framework (4) or later 
assessed analytically or empirically. As such, no empirical evidence supports the declaration 
of outcomes in general or the outcomes specified in the three-tier model as all that matter to 
patients (9). It is common for theories to lack explicit statements of assumptions (56). 
However, given the lack of empirical data and transparency, it is reasonable to suggest those 
assumptions are not backed by patient perspectives, statements, or cooperation.  
Despite the lack of empirical support, Porter maintained that VBHC is “the best way, and the 
only way, to drive sustained improvements” (4). If his statement is correct, such a framework 
would be of great interest, and indeed VBHC has had a tremendous influence in the policy 
debate. The global organization, International Consortium for Health Outcomes 
Measurement, is working to operationalize outcomes for a majority of medical conditions. 
Particularly in Sweden, several hospitals partly implemented VBHC (e.g., Karolinska, 
Sahlgrenska, and Uppsala University Hospitals). These ongoing implementations mandate a 
more thorough examination of VBHC. 
As with all frameworks (56), VBHC rests on several assumptions not explicitly stated. With 
the lack of evidence to support VBHC, it is reasonable to wonder if an independent 
researcher empirically or theoretically assessed any of these assumptions. In addition, a 
thorough examination of some underlying assumptions of VBHC might provide valuable 
insight on its scientific status and how to proceed with the ongoing implementations. 
A complete analysis of all VBHC assumptions is well beyond the scope of this thesis. The 
assumptions assessed herein concern the statements that outcomes are what matters to 
patients (41); the three-tier model specifies these outcomes, whereas the examples made are 
not meant to be exhaustive (9); and when choosing instruments, “standardized scales such as 
the SF-36 or the Beck Depression Index are preferable when available” (38). These were 
addressed earlier in this chapter. Thus, for the purpose of this thesis, the assumptions are 
interpreted as: 
A. Outcomes, and only outcomes, have intrinsic value to patients;  
B. Outcomes important to patients can be subsumed under the three-tier model; and 
C. Standardized outcome instruments measure the outcomes that matter to patients. 
Before proceeding with the aim of this thesis and how it relates to the assumptions discussed 
above, the next section (1.6) describes a concept important to assess these assumptions: 
patient participation. 
1.6 PATIENT PARTICIPATION 
At the same time health care struggles to improve care while maintaining costs, patients are 
gaining influence in health care at a system level (57) and in clinical care (58). Some 
publications have interpreted the increased influence as causing increased demand for 
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services (2) and others as a resource that mitigates the strain on the health care system (59). 
Several frameworks have detailed how to view or interact with patients in health care (eg. 60, 
61). Efforts have been made to bridge one such patient framework, patient-centered care, 
with VBHC. The analysis highlighted conflicting aspects where patient-centered care focused 
more on patients’ rights and needs and, as such, its connections were closer to quality than to 
costs (55). This thesis will not discuss specific patient frameworks and their relation to 
VBHC. Instead, it addresses the patient experience of care and health itself (62) in relation to 
VBHC. 
Patients have actively pursued efforts to gain influence, power, and autonomy on all levels of 
health care operations (59). Several perspectives have defended the idea of patient influence 
in care: as a civil rights issue by patient representatives (59), as a consequence of service 
dominant logic by economists (63), and as a consequence of social cognitive theory 
originating from psychology (64). 
More recently, patient-professional partnership (65-69) gained greater attention, emphasizing 
patients and professionals equally partaking in all parts of the processes in the health care 
operations. Instead of inviting patients to respond to predetermined questions and evaluate 
measurement design post-hoc, patients participate from the start. Patients influence questions, 
designs, and frameworks to the same extent as their professional partners.  
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 2 AIM 
The aim of this thesis is to assess assumptions (A-C) of VBHC in a chronic care setting. This 
overarching aim is addressed in four substudies, each with a specific aim. For clarity, these 
aims are shown with their corresponding assumption and setting information in Table 2.  
 
Table 2. Specific Aims Investigated in Substudies I to IV 
Substudy Assumption Rationale Specific aim 
I.  N/A Assumptions of 
VBHC have not been 
systematically 
assessed 
To characterize how VBHC is 
diffused and understood in the 
health care literature  
II.  Outcomes and only 
outcomes have 
intrinsic value to 
patients 
Patient initiation of 
care is valued by 
persons with RA (70, 
71), but is not an 
outcome and it is 
unknown if it 
improves outcomes 
To test the hypothesis that 
implementing a patient-
initiated system of care could 
improve clinical outcome in 
RA 
III.  Outcomes important 
to patients can be 
subsumed under the 
3-tier model 
The 3- tier model has 
been criticized as less 
suitable for chronic 
care (49) in general 
and RA in particular 
(72) 
To test the 3-tier model 
against patients’ views of 
value* in a chronic care 
setting 
IV.  Standardized outcome 
instruments measure 
outcomes that matter 
to patients 
HAQ is the most 
commonly used 
instrument to assess 
function in RA (73) 
To explore how persons with 
RA experience the use of the 
HAQ in care 
Note. *“Value” here does not refer to outcome/costs, but to the subjectivist notion of “what is 
important to me.” Substudy I investigated how earlier academic literature assessed VBHC 
and therefore lacks an assumption; Substudies II to IV were designed to empirically assess 
assumptions in rheumatology (the relevance of this setting is described in Section 3.4). 
VBHC = value-based health care; RA = rheumatoid arthritis; HAQ = health assessment 
questionnaire.  
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 3 METHODOLOGY 
This chapter briefly summarizes the methods of the respective substudies (Table 3, Section 
3.3.1), but puts emphasis on methodological considerations and integration in relation to the 
assumptions and the overarching aim. 
3.1 PHILOSOPHICAL ASSUMPTIONS 
Philosophers have suggested several ways of describing what science is (74-77). As Popper 
famously argued, scientific theories cannot be verified, but only rejected. In his argument, 
even one counter example is enough to reject an entire theory (74). However, Popper’s 
position has been criticized as idealized and disconnected from how science is really done 
(75). Particularity in social research, empirical findings commonly have multiple 
interpretations and therefore may only partially support a particular theory (78). Accordingly, 
in the substudies of this thesis, the word test was used both in the Popperian sense as a means 
to refute a hypothesis (II), but also in the meaning of critically applying a framework to 
suggest relevance to a setting (III). 
In accordance with Gough et. al. (79), this thesis distinguishes between configurative and 
aggregative research as it highlights differences between the aims of the substudies. 
Configurative research aims to find a way of understanding data and typically results in a 
model or theory (79). Aggregative research attempts to bring data together to support 
decisions and is typically helpful when creating societal policy (79). Often, research is both 
configurative and aggregative. For example, it might aim to structure or separate data in a 
way that makes it easier to understand, but at the same time inform, decisions. This is called 
integrative research (79).  
To evaluate VBHC, this thesis uses the term research program, which originated from 
Lakatos (76). A research program is a set of beliefs about reality and about how knowledge 
can be gained. In this thesis, the VBHC theory itself is referred to as a strategic framework, 
whereas the practice and the assumptions behind the strategic framework are referred to as a 
research program. Lakatos (76) exemplified research programs as Marxism, Freudianism, or 
the Newtonian view of gravity. Every research program includes a hierarchy of hypotheses. 
They have a core of central hypotheses and then layers of less stable (auxiliary) hypotheses 
that protect the central hypotheses from refutation. The assumptions of VBHC introduced in 
the background chapter can be seen as hypothesis in this sense. In VBHC, assumption A 
would be closer to the core than assumption C, because a refutation of assumption A would 
have greater consequences for the research program than would a refutation of assumption C. 
In addition, there are undoubtedly hypotheses in VBHC that are even more important than the 
assumptions assessed here. For example, a core hypothesis seems to be that “one cannot 
manage what one cannot measure.” This core hypothesis is protected by auxiliary hypotheses 
such as defining measurements as any kind of quantization. If new evidence threatens to 
refute this core hypothesis, then VBHC researchers are more likely to revise the definition of 
measurement than to abandon the hypothesis that only measurable phenomenon can be 
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managed. As will be subsequently argued in the discussion section, similarly assumption A is 
affected by how outcomes are defined. 
In addition, every research program has a specific method to resolve discrepancies, handle 
new data, or solve problems within the program. Lakatos called this problem-solving 
machinery “heuristic” (76). In VBHC, a common way to deal with problems is to look for 
cases that have solved the problem and then incorporate those solutions into the theory. A 
contrasting method common in biomedical science would be to pose hypotheses and then try 
to test their consequences of the hypothesis. As a final characteristic, the research program 
makes predictions based on its hypothesis and problem-solving machinery (76). For example, 
VBHC predicted that if all levels of outcomes were measured in the three-tier model, then 
health care costs would invariably decrease (38).  
If one research program’s predictions are more correct than those of a competing program, 
then the program is said to be progressive (76). The concept of progression is important in 
Lakatos analysis because it explains that throughout the history of science, early models and 
hypotheses have needed time and patience to develop into full scientific theories. It is 
therefore reasonable, Lakatos asserted, that new theories fail to explain part of the available 
data. Most scientific theories were developed progressively through iterations while 
competing with alternative research programs. (76). 
In parallel, Kuhn’s (75) paradigm theory was used in this thesis to account for the 
epistemological stance of the thesis. The paradigm theory is sometimes applied to 
frameworks of similar complexity as VBHC. It is, in addition, more popular and widespread 
than the theory of research programs. However, the paradigm theory fails to account for 
several aspects relevant to VBHC. It primarily lacks an understanding of multiple parallel 
research programs, structured refutation, and the idea of differences in progression. Some 
scholars have suggested a “post-Kuhnian” view of paradigm (80) in which several paradigms 
compete in a way similar to Lakatos’ (76) theory of research programs. To avoid confusion, 
this thesis uses the term research program to refer to VBHC and paradigm to refer to an 
epistemological stance. 
The research program’s focus on prediction is at odds with the categorization between 
configurative and aggregative research. Configurative research does not serve to make 
predictions but rather to configure data in a way that provides a feeling of understanding. To 
bridge this disparity, this thesis takes a pragmatic standpoint. Specifically, this thesis assumes 
that the usefulness of a theory is a product of its “problem-solving capacity” (81). The 
parallels to the problem-solving machineries discussed above are obvious, even though 
pragmatism does not limit the purpose of a theory to that of making predictions. The 
pragmatic paradigm assumes the problems of the real world as they appear to the inquirer. It 
seeks to solve problems with the “best” possible method without considering the 
epistemological origin of the specific method (82). However, this approach assumes the 
usefulness of a design is known in advance of performing the study, which can be 
considerably difficult (83).  
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In line with this, this thesis views the dichotomy of qualitative and quantitative methodology 
(84) and paradigm (85) as misleading. Instead, references to quantitative or qualitative in this 
thesis should be seen as references to specific data rather than as packages including 
ontological and epistemological assumptions. However, for the purpose of communication, 
the terms qualitative and quantitative methods are used in this thesis to summarize the 
methods used for a particular type of data. This rejection of separate qualitative and 
quantitative paradigms aligns with pragmatism (81) but is not particular to a specific 
tradition. The same assertion has previously been made by researchers focused on mixed 
(86), qualitative (87), and quantitative (88) methods.  
3.2 OVERARCHING METHODOLOGY 
A majority of management research is framed by a knowledge gap that forms the basis and 
motivation for the research aim (56). Instead, an aim can be formulated based on 
problematization of the literature and its underlying assumptions. As described by Alvesson 
et al, “Problematization research typically involves a more narrow literature coverage and in-
depth readings of key texts, with the specific aim of identifying and challenging the 
assumptions” (56). Assessing assumptions is particularly relevant when political factors or a 
social interest bias govern knowledge production (56). The assumptions are often 
unpostulated and unlabeled (89). As such, it has been suggested (56) that implicit or weakly 
articulated assumptions are of greater interest because they are more difficult for researchers 
employing the theory to notice. Further, assumptions that are not instrumental in explaining 
known empirical findings are more likely to be false (56).  
The problematization method (56) consists of identifying relevant literature, articulating 
assumptions implicit in the literature, evaluating assumptions in terms of likeliness to be 
false, developing alternative assumptions through comparison with other literature, discussing 
assumptions with stakeholders and assessing who will be affected by changed assumptions, 
and evaluating whether alternative assumptions are likely to generate a well-spread theory. In 
moving iteratively through these steps, assumptions relevant to the assessment emerge (56). 
Problematization of the VBHC and adjacent literature was assessed in the background 
chapter of this thesis. Although discussions with stakeholders (patients, professionals, civil 
servants, politicians, management consultants, and academics) contributed to shaping the 
literature included in this thesis, their respective contributions were omitted. Detailing how 
this thesis arrived at those specific assumptions and tracing it through all the iterations would 
have been a study of its own. The method’s final step: evaluating whether alternative 
assumptions are likely to generate a well-spread theory was not performed in this thesis 
because the aim was not to produce a well-spread theory or new assumptions. 
The problematization methodology does not prescribe how assumptions should be evaluated 
(56). In assessing the assumptions of VBHC, this thesis took a mixed-methods approach. This 
decision was a consequence of rejecting the distinction between qualitative and quantitative 
paradigms. The specific methods were selected, as described from the pragmatic standpoint 
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(81), simply because they were assumed to provide the most illuminating answer based on 
the specific aim of the inquiry. Further, as aligned with Tashakkori and Teddlie’s (90) 
recommendation, the thesis sought to integrate qualitative and quantitative findings and 
present them in a combined fashion whenever feasible. This highlights contradictions and 
alignments of findings from different methods (i.e., methodological triangulation). A 
summary, the hierarchy of the philosophical assumptions, and the methodology are illustrated 
in Figure 3. 
Figure 3. Philosophical and Methodological Positioning of the Present Thesis 
Pragmatism 
Theory of research programs 
Value-based health care 
Problematization 
Mixed methods 
approach 
Swedish rheumatology 
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3.3 DESIGN 
The designs of the substudies are outlined in Table 3. 
Table 3. Outline of Substudies in the Thesis 
Substudy Perspective Design Sample Data source Analysis 
I Retrospective 
Configurative 
Sequential 
mixed methods 
255 
citations 
Literature, 
citation registry 
data 
Qualitative and 
quantitative content 
analysis, non-
parametric tests 
II Prospective 
Aggregative 
Randomized 
controlled trial 
131 
persons 
with RA 
Blinded assessor, 
patient reported, 
laboratory tests 
Longitudinal mixed 
models, non-
parametric tests 
III Retrospective 
Integrative 
Qualitative 
Abductive 
22 persons 
with RA 
Semi-structured 
interviews 
Qualitative content 
analysis 
IV Retrospective 
Configurative 
Qualitative 
Inductive 
40 persons 
with RA 
Semi-structured 
interviews 
Thematic analysis 
Note. RA = rheumatoid arthritis 
3.3.1 Summary of methods 
This thesis used quantitative and qualitative data. Quantitative data were used to investigate 
causes in an randomized controlled trial (RCT) (II), correlations between understanding of 
VBHC and journal impact (I), as well as to describe citation counts and the study population 
in the RCT (I, II). Qualitative data were used to capture the understanding of VBHC (I), 
patient conception of value (III), and patient experiences of an outcome measure (IV). 
Substudies I to IV were conducted independently, even though Substudies III and IV partially 
shared data. 
In Substudy I, the most cited VBHC article was categorized into conceptual aspects using 
content analysis. Articles citing the VBHC article were categorized to evaluate how the 
conceptual aspects were understood according to the structure of observed learning outcomes 
(SOLO) taxonomy. Substudy II was an 18-month, controlled blinded endpoint, two-center 
randomized study with 131 RA patients. The intervention group individually initiated 
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appointments when they perceived a flare. 28-joint disease activity score (DAS28), 
satisfaction with care, confidence in care, and number of appointments with the 
rheumatologist was evaluated in comparison with standard care. In Substudies III and IV 
respectively, persons with RA were interviewed to analyze abductively the three-tier model 
and to evaluate a commonly used outcome measure. Substudy I did not test a VBHC 
assumption and is therefore presented first, followed by setting and Substudies II to IV. 
3.4 CHARACTERIZING THE MOST-CITED VBHC ARTICLE 
A sequential mixed method was developed, and used to characterize how VBHC was 
understood. The term exploratory is often used for mixed-methods studies that start with a 
qualitative investigation, whereas the term explanatory describes those that end with a 
qualitative investigation (91). This substudy started with a quantitative exploration and then 
alternated between qualitative and quantitative data, as outlined in Figure 4. It is worth noting 
that Substudy I took on a broader aim than would have been justified by the overarching aim 
of this thesis. It not only reviewed assumptions of VBHC in a chronic care setting, but also 
characterized understanding including and beyond assumptions in all settings where VBHC 
had been applied.  
Figure 4. Method Used in Substudy I. Blue signifies analyzing quantitative data and green, 
qualitative data. 
The most-cited VBHC article written by Porter was identified in Web of Science. If citations 
monotonically correlated to trend impact, then this article could be seen as the main cause of 
VBHC interest from other researchers. Making this assumption, the most-cited article was 
referred to as the trend-starting article. However, the assumption, and thus this label, are 
questionable and are not used here. In addition, a qualitative analysis of all VBHC articles 
would certainly have provided more solid data on which article had the greatest trend impact. 
However, the most cited article turned out to be the main VBHC article on outcomes, and an 
in-depth analysis thus aligns with this thesis’ focus on outcomes. 
From the most cited article, a nominal scale was developed using qualitative content analysis 
(92), by openly coding the text in the article and then inductively categorizing the codes. The 
Identify 
most cited 
article 
Extract 
conceptual 
aspects 
Collect 
data on 
citing 
articles 
Categorize 
citing texts 
Analyze 
statistically 
Examine 
data to 
explain 
statistics 
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categories were formed to maximize inner homogeneity and other heterogeneity (82). This 
analysis rendered five categories in which everything written in the most-cited article could 
be sorted. It also meant that every article citing this article would refer to one of the five 
concepts represented in the categories, assuming the citations were correct. In the substudy, 
the method was referred to as thematic analysis according to Braun and Clarke (93). Their 
step-by-step guide coincides with the method employed. However, in terms of tradition and 
assumptions, the term content analysis would have more appropriately named the process 
(discussed further at the end of section 3.3.3). 
Next, all articles citing the most-cited article (as of 2 May 2014) were classified in terms of 
concept and understanding. This classification was important to enable analysis of 
longitudinal trends to achieve a broader understanding of frequencies unattainable by 
qualitative analysis alone. To enable this classification, text referring to the most-cited article 
was extracted using a semi-automated text-mining technique that flagged all parts of the 
articles referring to the most-cited article (NVivo v. 10.0). Quantitative data on publication 
year and impact factor were extracted from public registries (94). All extracted citations were 
quantified using the nominal scale developed with content analysis and SOLO, an ordinal 
five-step scale from education assessment (95). In this phase, the method has a similarity to a 
meta-analysis method in case studies—quantitative case survey (96, 97)—which seeks to 
formally code and quantify qualitative cases in order to apply statistical methods.  
There are two well-recognized taxonomies for understanding: Bloom’s taxonomy (98) and 
Bigg’s SOLO taxonomy (95). Bloom’s taxonomy groups learning into categories labeled 
remember, understand, apply, analyze, evaluate, and create, whereas SOLO distinguishes 
between no idea, one idea, many ideas, relate, and extend (99). Thus, SOLO categorizes 
understanding as misunderstanding a concept, understanding one concept, understanding 
more than one concept, understanding the relations between concepts, or extending and 
improving the concepts. For the purpose of Substudy I, Bloom’s taxonomy proved too 
granular to capture data. For example, it was difficult to distinguish between remembering 
and understanding based on the citing texts. In addition, the substudy primarily concerned 
understanding, whereas Bloom’s taxonomy also addressed thinking strategies such as 
analyzing and creating (98). Because the SOLO taxonomy did not include these, it had a 
clearer progression of understanding between the levels, making possible treating it as an 
ordinal scale, and thus performing more advanced statistical analysis.  
The data were analyzed with descriptive and inference statistics using medians, interquartile 
ranges, and nonparametric tests because the scales were nominal and ordinal (78). A χ2 test 
for trend was used for longitudinal analysis, and Spearman’s Rho when analyzing non-
normally distributed correlations. To explain the quantitative findings in greater depth, the 
coded data were reexamined for additional insight such as what kind of misunderstandings of 
VBHC occurred, rather than just the frequency of misunderstanding. 
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3.5 EMPIRICAL SETTING AND STUDY PARTICIPANTS 
RA was chosen as a case for analyzing the assumptions of VBHC. This section describes this 
setting and the study participants. Because the purpose of this thesis was not to develop 
VBHC specifically within rheumatology, or adjust it to rheumatology, both the empirical 
setting and the medical condition (RA) are addressed here rather than in the background 
chapter.  
Rheumatoid arthritis is a chronic inflammatory disease with loss of function due to structural 
joint damage (100). Remission and prevention of joint damage can be achieved with early 
discovery and treatment (101). The disease affects the ability to work and many other aspects 
of life, such as functional, sexual, social, and emotional (102). Patients are frequently 
assessed and therapy adjusted until remission has been reached (103).  
Outcome measurements are registered in the Swedish Rheumatology Quality Registry (104) 
(e.g., DAS28, EuroQol five dimensions questionnaire, Stanford’s health assessment 
questionnaire—disability index (HAQ), work ability, pain according to visual analog scale 
(VAS)). Patients seeking care enter these data through a computer interface before their visits 
(105) with a nurse or, if necessary, a physician (106). Interprofessional care and rehabilitation 
are important for successful care (107, 108). The presence of RA increases the risk of other 
diseases such as osteoporosis (109), and certain treatments aggravate this effect (110). Other 
treatments increase the risk of cardiovascular mortality and morbidity (111), serious 
infections (112), and nonmalignant skin cancers (113). (For the purpose of this thesis, RA 
including theses complications is assumed to be a single medical condition.) These risks 
mean that patients seem to experience many of the aspects detailed in the categories of the 
three-tier model, including long-term consequences of care. 
Treatment guidelines are based on primarily assessment of DAS28. The DAS28 is a 
composite index summarizing inflammatory activity in joints and blood with the patient’s 
reported global health. It is calculated using graded tenderness and swelling in 28 joints 
(excluding the feet), erythrocyte sedimentation rate, and patient-reported VAS-general health 
(114). Values below 3.2 are considered low disease activity (115); and values below 2.6, 
disease remission (116). The least clinically significant difference of DAS28 is 0.6 (117). 
Another frequently used registry outcome, HAQ, is addressed in section 3.2.3. 
In Sweden, RA care is highly relevant to questions about VBHC applications. When Boston 
Consulting Group rated countries ready for a “VBHC transformation,” Sweden came out on 
top (118). Porter et. al. also argued that the open publication of outcome and process 
measurements (Öppna jämförelser) already increased value (4(p376-7)). The specific setting 
of rheumatology was interesting due to criticism of how VBHC applied to the care of persons 
with chronic diseases (49) in general and RA in particular (72). The rationale in this sense 
was to assess VBHC in one of the settings where it is most difficult to apply (i.e., using 
critical case sampling—”If it works here, it will work anywhere” (82(p266)). Due to the 
specific design of this thesis, Swedish rheumatology is suitable for two additional reasons: 
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1) Swedish rheumatology has a well-developed quality registry that forms a basis for
evaluating outcomes. This registry covers process measures, physician-judged
variables, and laboratory data as well as patient-reported outcome measures. The
registry includes patients in all socioeconomic and demographic groups.
2) Rheumatology patients are in the forefront of patient participation, ensuring rich
accounts of the patient perspective is available. In addition, rheumatology has a strong
tradition in adjusting outcomes to better suit the patient perspective (119).
Study participant demographics are outlined in Table 4. 
Table 4. Study Participants’ Characteristics 
Study 
Age 
Mdn 
(IQR, range) 
Number 
female (%) 
Disease activitya 
Mdn 
 (IQR, range) 
Disease duration 
Mdn 
 (IQR, range) 
Satisfaction with 
careb 
Mdn (IQR, range) 
RCT (II) 64 (55-71) 41 (61) 3.4 (2.7-4.7) 5 (2-12) 93 (82-97) 
Three-tier 
evaluation (III) 
55 (30-82) 17 (77) Low (low-high) 11 (2-48) Satisfied (not 
satisfied-satisfied) 
HAQ 
evaluation (IV) 
55 (27-82)c 32 (80) Low (low-high) 11 (1-48)c Satisfied (not 
satisfied-satisfied) 
Note. Mdn = median; IQR = interquartile range; Mdn (IQR) is displayed for the RCT, and Mdn 
(range) for the evaluations; adisease activity in the RCT shows DAS28 and in the evaluations, patient-
perceived disease activity on the three-step scale of low, medium, or high; bsatisfaction in the RCT 
shows VAS and in the evaluations, dichotomous patient assessments of generally satisfied or 
generally not satisfied; cage data on one patient and disease duration data on four patients are missing 
because they were not systematically collected. 
3.6 LINKING ASSUMPTIONS, DESIGN, DATA COLLECTION AND ANALYSIS 
3.6.1 Outcomes and only outcomes have intrinsic value to patients 
To assess the assumption, “Outcomes and only outcomes have intrinsic value to patients,” it 
was not enough to show that specific non-outcomes are valuable. Specifically, VBHC makes 
the argument that non-outcomes can be perceived as valuable because they affect outcomes 
that in turn have intrinsic value. Assessing this assumption was therefore a matter of 
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assessing if a valuable non-outcome would affect outcomes (as predicted by VBHC). Thus, it 
was a matter of causality. Will a valuable structural change such as allowing patients to 
initiate their own appointments (70, 71) cause a change in outcomes? For this purpose, RCT 
was ideal because randomization mitigates the effect of confounders.  
The RCT designed to test this causality was an 18-month, controlled blinded endpoint, two-
center randomized trial. Treatment followed local guidelines primarily based on DAS28 
assessment. Another frequently used registry outcome, HAQ, is addressed in Section 3.2.3. 
Patients were recruited for inclusion at change of attending rheumatologist because these 
were the only patients naïve to the intervention (convenience sampling). Using a computer 
generated pseudorandom sequence, 131 persons with RA were randomized to intervention 
(n = 64) or control (n = 67) groups. The intervention group was guaranteed appointments 
with a rheumatologist within 10 working days if they subjectively experienced a flare in 
disease activity. Control group participants were booked for appointments in advance, 
according to standard guidelines. Independent assessments were performed in the two groups 
at 0, 3, 6, 12, and 18 months. The DAS28 was used as a primary outcome. In addition, the 
study collected HAQ, data on satisfaction with and confidence in care measured on the VAS, 
and the number of visits. 
Quantitative data were analyzed using non-parametric tests and linear mixed models. Non-
parametric tests are applicable to non-normally distributed data, as compared with parametric 
tests that assume the data are normally distributed. Whereas parametric tests analyze 
differences between group means, non-parametric tests examine differences in distribution. 
Descriptive statistics of normally distributed interval data can be characterized using means 
and standard deviation, whereas medians and ranges apply to non-normally distributed 
ordinal scales (78).  
The primary outcome of the RCT—DAS28—was analyzed longitudinally. This can be done 
with mixed model, ANOVA-tests, and χ2 test for trend. The ANOVA tests cannot use 
missing data, and the χ2 test for trend is suitable for nominal scales (it was used when 
assessing the longitudinal change of citations of VBCH, described in the section above). 
Because DAS28 was normally distributed and some participants had missing values, a 
longitudinal mixed model was most suitable. There are several types of mixed models, and 
here an unstructured mixed model was selected based on an information-theoretic approach. 
That is, the longitudinal model was an average of several feasible models. This average 
compensated for any model-specific problems and provided the most robust inference. By 
using this method, it was less necessary to account for influence of individual variables (120). 
However, to further increase accuracy, the model was nevertheless adjusted by three 
variables that demonstrated differences between the intervention and control groups when 
analyzed categorically: sex, disease activity, and age. The Mann-Whitney U test was used to 
compare ordinal and interval scales, and Pearson’s χ2 test for nominal scales in exploratory 
analyzed secondary outcomes. Significance level was α = 0.05.  
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 In the study plan for the RCT, the primary outcome was the area under the curve of DAS28 
over time. The intention was to emphasize the time dimensions of outcomes (similarly to 
Fries’ outcome model, Figure 1). However, this approach failed to consider the problem of 
missing data. Area calculations under the curve required more than one data point and were 
not feasible because data were missing. To avoid excluding patients with missing data, the 
actual DAS28, unaccounted for in the area under the curve, was used as a primary outcome. 
This way, the longitudinal mixed model could account for missing values and more data 
could be included. However, the purpose of choosing one primary outcome and letting the 
others be secondary (or exploratory) in advance was to reduce the risk of false positives 
(Type 1 error), because the risk increases with the number of performed analyses (78). In this 
case, the area under the curve for DAS28 was never calculated and thus never tested. 
Therefore, the risk of false positives did not increase even though the final analysis deviated 
from the study protocol. 
3.6.2 Outcomes important to patients can be subsumed under the three-tier 
model 
The assumption, “Outcomes important to patients can be subsumed under the three-tier 
model” concerns whether patient conception of value aligns with the three-tier model 
categories. This model could have been evaluated through a patient survey. However, to 
assess the assumption and intricacies of value conceptions, qualitative data were assumed to 
provide greater depth in the mechanisms of how potential outcomes interact and in the 
possibility to explore new hypotheses iteratively.  
An interview guide was designed based on previous interviews performed in another research 
project and literature from the health care management field. The guide was expanded 
iteratively as new topics emerged. Such an iterative revision was important for the results 
because the interview guide was originally intended to study patient experience of value in 
the care process. After six interviews, the guide was broadened to include value outside of 
care. This change was made because it became obvious that most value to persons with RA 
was created outside of health care. Although this expansion required a renewed ethical 
approval and thus slowed reporting of the results, it allowed interesting findings to appear. 
The interview guide was consequently expanded to include more aspects of life outside of 
care. Interviews continued until perceived saturation, rendering 22 interviews. 
The interviews were analyzed with abductive content analysis (92) in relation to the three-tier 
model, but thematic analysis (93) was also considered. The distinction between content 
analysis and thematic analysis is not self-evident in the literature. Content analysis is usually 
concerned with capturing the totality of the data (121) and with the tradition of using 
categories for frequency counts (93). Capturing the totality of data content is often analyzed 
by condensing meaning units—an attempt to summarize sentences in a more condensed form 
but with preserved meaning. In addition, content analysis often distinguishes between 
manifest (“obvious”) and latent (“between the lines”) interpretations (122). In contrast, 
thematic analysis does not make this distinction (123). It integrates the data with knowledge 
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about the setting (93, 123) and generally focuses on larger meaning units such as full 
paragraphs (93). Further, content analysis often concerns identifying mutually exclusive 
categories whereas themes are generally assumed to have common denominators (121). 
Content analysis was suitable for this substudy because the analysis was performed 
abductively (124) to assess the three-tier model, which consisted of mutually exclusive 
categories, and to encompass the totality of the data. Similarly, the substudy investigating 
concepts in the most-cited VBHC article also fit better with content analysis, but for a 
different reason. In that substudy, where the interest was manifest content, it was crucial to 
include the totality of data. In addition, the developed nominal scale was created to enable 
quantification.  
In pursuit of more fully understanding participant conception of value in the interview data, 
two additional analytical frameworks were considered alongside the three-tier model: the 
international classification of function (ICF) (125) and the value compass (24). These 
considerations were made before the thesis project was solely directed at VBHC. The ICF 
was omitted because several publications already used it to classify value according to 
persons with RA (126-128). The value compass was omitted because it separated outcomes 
into functional health status, clinical outcomes, satisfaction, and costs. Its emphasis on 
satisfaction itself, costs, and clinical outcomes was less applicable to the data than was the 
three-tier model. Most notably, the data on costs were very shallow despite costs being a 
topic in the interview guide, and clinical outcomes were not valuable to the participants. 
3.6.3 Standardized outcome instruments measure outcomes that matter to 
patients 
The assumption, “Standardized outcome instruments measure outcomes that matter to 
patients,” concerns outcome instruments used in care delivery. For this study, the choice was 
made to look at experiences of measurements in care rather than perceptions of a specific 
instrument. Although this decision limited the instruments available for evaluation, it focused 
the evaluation towards measurements seen as feasible enough to be incorporated in everyday 
care. The specific setting of RA is discussed in Section 3.4. The next paragraph details the 
considerations made in choosing the specific instrument in RA. 
Of the outcomes covered for RA in the Swedish Rheumatology Quality Registry, two were 
extensively used, agreed with the three-tier model, and have been confirmed to be valuable to 
patients: global pain and functional level (129). In the registry, these two outcomes are 
measured with VAS for global pain level and HAQ for functional level. Whereas VAS is 
unidimensional, HAQ consists of 20 items that encompass different functional aspects. 
Therefore, valuing functional ability might not be the same as valuing every functional 
dimension measured in HAQ. For example, one dimension of HAQ covered opening cans; it 
would be perfectly possible to value functional ability as a whole, while not valuing the 
ability to open a can. That is, persons with RA might interpret functional ability differently 
than did the HAQ developer. In addition, HAQ has been suggested as an outcome suitable for 
VBHC (130). For these reasons, exploring HAQ was deemed to be of greatest relevance to 
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 the assumption and to generate the highest impact in this setting (i.e., high-impact case 
(82(p266))).  
This specific aim was then addressed using the semi-structured interview data collected to 
assess the three-tier model (22 interviews) and interview data from a separate research project 
that investigated the role of decision-support systems in the care process (18 interviews). 
These datasets were selected because both contained detailed accounts of the HAQ. Often, 
HAQ was brought up as a topic by the respondents themselves, which supported the 
interpretation of HAQ as an instrument of relevance to patients and thus relevant to 
investigate. The interview data were analyzed by the thesis author with thematic analysis (93) 
using the computer program NVivo v. 10.0. The aim was to explore the experience of HAQ 
in interaction with the care setting. From that exploration, the study captured relevant 
findings inductively—it became less important to capture all data in the generated themes. 
For example, some participants had difficulty discussing some aspects of HAQ during the 
interview; these data were not formed into a theme (such as “difficulty discussing HAQ”) 
because it would not contribute to the research question. As was reasoned, thematic analysis 
is generally more applicable when the generated findings have common denominators and do 
not encompass all collected data. 
To aid analysis of HAQ experiences, two separate theoretical frameworks were explored: 
institutional ethnography (131) and concept theory (132). These frameworks provided 
valuable insights concerning the findings. Institutional ethnography highlighted how clinical 
encounters could be controlled by the communication that HAQ allowed, and concept theory 
showed how specific functional aspects could become more important because of the 
attention given to them through HAQ. However, both analyses were removed from the 
substudy manuscript to adhere to word limits and because they were not necessary for the 
substudy’s central message. 
3.7 APPLYING CRITERIA FOR RESEARCH QUALITY 
In problematization methodology, quality is determined by the assumptions selected for 
problematization. Similar to the pragmatic paradigm idea of usability, an assumption is more 
interesting if it contributes significantly neither to understanding of a theory nor to explaining 
empirical finding (56). The VBHC assumptions were selected for their lack of theoretical 
contribution to the overall framework and expected practical implications. This section 
describes the steps taken in this thesis to ensure the empirical findings were trustworthy. 
Further, the different research traditions tied to quantitative and qualitative data have their 
own criteria for quality but have similar traits (133) and will therefore be presented 
thematically. 
The first trait concerns the extent to which the findings agreed with the object of study. This 
means taking necessary steps to ensure it is reasonable to believe the findings are “true.” 
When using quantitative data, this is often called internal validity (134), which concerns 
choice of statistical methods and power calculations and avoiding confounders (78). In the 
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RCT, power calculations (power 80%) ensured a sufficient sample size and the mixed model 
was adjusted for confounders. In addition, scales with non-equal intervals were treated as 
such by avoiding parametric tests. When handling qualitative data, the relation to truthfulness 
is often called credibility and concerns choices made to ensure trustworthiness in the 
interpretation. Realist researchers in general would argue for member checks; that is, asking 
research participants to verify data and interpretations (133). This member-check technique 
was employed in the interview study of the three-tier model, where some of the respondents 
left comments about the finished model. Constructivist and critical researchers in general 
would instead argue for extended engagement with the data and collaboration with 
participants in interpretation, respectively (135).  
The second trait concerns the extent to which the findings are applicable outside the object of 
study. In the tradition of working with quantitative data, this is usually termed external 
validity or generalizability (134). This validity is achieved mainly by avoiding systematic 
errors when collecting samples from the studied population (78). The RCT used convenience 
sampling, which is common in RCTs but limits generalizability. However, this RCT was a 
two-center trial, which made the findings less dependent on the specific setting of one center. 
In addition, the RCT employed usual treatment guidelines instead of a fixed protocol. That 
type of pragmatic RCT closer resembled the real situation of everyday care (“ecological 
validity”). Qualitative researchers also have the ambition of applying findings outside the 
study setting. This applicability is often called transferability and concerns reporting the 
findings in such a way that a reader can judge if the findings apply in a different context 
(133). This divide between qualitative and quantitative terminology is sometimes 
characterized by the terms contextualized data, meaning data with a detailed description of 
the setting, and decontextualized data, often referring to randomly selected samples (136). 
The interview substudies were contextualized by reporting on all factors of the setting 
believed to impact the findings. Similar to contextualization, reporting of the RCT involved a 
description of the population (“baseline data”) and setting, as is the quantitative convention 
(134). Further, despite the divide of terminology, researchers working with quantitative data 
also attempt to transfer findings between different populations or settings. 
The third trait considers the extent to which the researcher affects the findings. Quantitative 
methods often call this objectivity (133) and see it as a product of the methods used—
including stating the hypothesis and α-values in advance, as well as blinding researchers, 
research participants, and assessors (137). Therefore, in the RCT, the qualitative assessment 
of the joints necessary to calculate the DAS28 was conducted by a blinded assessor. 
Similarly, the categorization of articles citing the most-cited VBHC article was performed 
independently by two researchers blinded to each other’s interpretations. In the qualitative 
tradition, this is often called confirmability and can concern actively looking for mistakes and 
data contradicting the findings (78) or comparing the findings of different researchers 
(“investigator triangulation” (43)). In the interview substudies, confirmability was ensured by 
alternating between the perspectives of making the data fit and looking for data that 
contradict the findings. The literature showed findings similar to the substudy of the three-tier 
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 model and this strengthens confirmability. In addition, the critical tradition has suggested 
detailed reporting of the researcher’s preconceptions (“reflexivity”) (135), nowadays used 
across many qualitative traditions (82).  
The final trait addresses the extent to which the findings are affected by factors that are not 
the object of study. It concerns whether the study is repeatable. For quantitative data, this 
could be measured though reliability—the idea of conducting multiple measurements and 
then assessing agreement (78). Thus, it represents whether the instrument is reliable. For 
qualitative data, it is more common to speak of dependability, meaning close attention is paid 
to factors outside the object of study and their interactions. (These factors are often called 
context; this thesis instead uses the term setting, but in this thesis the terms would be 
interchangeable). Observations of these factors should be closely reported (138). Some 
studies have argued that dependability concerns an in-depth description of changes in the 
researcher during the project because the researcher is affected by the study and the context 
(133). This concept parallels the idea of reliability because some qualitative researchers 
would argue that the researchers themselves are the research instrument (139), suggesting the 
major part of the analysis and interpretation take place in the researcher’s mind. Thus, 
consistency in “the instrument” is consistency in study design, data collection, and analysis. 
Hence, dependability concerns the practice of research, differing from confirmability that 
concerns interpretation of the findings. Dependability in the present thesis is judged by the 
reader based on the substudy reports.  
3.8 ETHICAL CONSIDERATIONS 
This section focuses on ethical aspects of the studies involving research persons. The 
Regional Ethics Board in Stockholm, Sweden granted formal approval (2008/1226-32/3, 
2009/895-31/5 and 2012/1911-31/5). 
3.8.1 Informed consent 
Study participants made the decision to participate in the substudies without the presence of 
anyone involved in their care. This separation was important to mitigate the risk they would 
feel pressured to participate. The researcher provided them information in a nontechnical 
way, and participants could retract their consent at any time (140). Decisions to participate in 
the RCT (II) were made with a nurse who was not involved in the patients’ care. The 
decisions to participate in the interview studies (III, IV) were made with the interviewer over 
the phone after the participants’ physicians informed patients in advance that a researcher 
would contact them. If their physicians (or anyone else involved in care) directly asked for 
their participation, it could give the impression that declining to participate might affect the 
physician-patient relationship or result in worse care. In chronic care, patients are often 
followed by the same physician and, because of this, relationships with the physician can be 
of extra importance. These considerations were made before the start of the studies, but 
continuity and relationship were later confirmed to be important in the findings of this thesis 
(III).  
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The RCT (II) concerned an intervention in care that could possibly harm patients. This 
particular intervention put demands on the patient’s autonomy and transferred responsibility 
for care to the patient. Therefore, it was important to exclude persons who, due to impaired 
judgment or reasoning, could not be expected to assess the information given about the study 
and might not be able to assess their own health during the trial. In the case of impaired 
judgement, any consent given would not be considered informed consent (140). This can be 
especially tricky when the research concerns interventions in the care processes because 
research subjects have been demonstrated to have difficulty distinguishing between care and 
research (141). In addition, the checkpoints that assessed patients every third month (initially) 
acted as a safety net and identified any patient who had not sought care despite high disease 
activity. 
3.8.2 Data collection 
When digging deeply into experiences of care, accounts of misconduct in care may arise. 
Gaining this information during an interview could in turn infer a duty to act. However, due 
to the limited resources available for this research, it would not be possible to engage in such 
accounts. Instead, participants with such experiences would be referred to other functions in 
place to handle those issues, such as the Patient Claims Panel. Further, it could be argued that 
engaging in such accounts could harm the participant because researchers seldom possess the 
expertise required to act.  
The interview guide concerned very personal areas such as death and sexuality. As such, the 
interview process could evoke bad memories or discomfort. Old memories could be brought 
back to life with potential psychological suffering. This could be problematic because the 
researchers did not have therapeutic experience to account and handle the memories and their 
consequences. Instead, they would advise professional help if any such harm occurred. 
Further, even though this is an important risk, the research project’s expected benefits 
outweighed this risk.  
For reasons of equity, the burden of research should be evenly distributed among research 
subjects (140). One, for example, should not perform more research on people who are close 
by for convenience reasons. In addition, such convenience sampling decreases the quality of 
the findings (82) and makes it less justifiable to take the time of and expose research subjects 
to risks. However, the RCT used convenience sampling. This was acceptable because the trial 
could not have been performed by using random sampling of all persons with RA. 
3.8.3 Data handling 
Interpretation of the interviews could affect the patient perspective, mixing views that 
originated from the researcher with the patients’ opinions. This issue concerns research 
quality (discussed above as confirmability), but also has an ethical aspect. Qualitative 
researches often give voice to unheard or marginalized groups, and any clouding of their 
experience would affect how the group is understood and conceptualized, with potential 
effects on, for example, stigma. However, the particular population of this thesis—persons 
28 
 with RA in Sweden—has a strong influence in the policy and health care debates due to their 
influential patient association. Thus, this issue was handled by a careful examination of the 
data, assuming different perspectives (III, IV), and asking participants for clarification when 
necessary (III).  
Speaking of “persons with RA” as influential assumes the RA population is relatively 
homogeneous. However, that is unlikely to be the case. Perhaps subgroups of patients are not 
represented in the interviews. If that is the case, the research could be a disadvantage to the 
subpopulations not represented. Presenting the normative and aggregating nature of the data 
as a model or as themes rather than different narratives could make alternative perspectives 
less salient. This would not necessarily harm those subgroups physically or mentally, but it 
could harm their interests in terms of influencing care. 
Handling the interview and RCT material involved trade-offs between integrity and 
efficiency, or validity. If the only priority were integrity of the research, then only one 
researcher would handle all the data. In the case of interviews, this would reasonably be the 
interviewer. However, that would be at odds with the validity gained from sharing data for 
investigator triangulation (III, IV) or from asking a statistician for advice (II). A further 
efficiency aspect comes in hiring external transcribers to process the interview data. This 
thesis used investigator triangulation, statistical advice, and professional transcribers. 
Integrity was protected by anonymizing data to the greatest extent possible, using secure 
encrypted data storage, and ensuring only one researcher had access to the identity of the 
research persons. 
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 4 FINDINGS 
The findings, grouped by substudy, are outlined in Table 5.  
 
Table 5. Overview of Substudy Findings 
Specific Aim Main Result Substudy Conclusion 
I. To characterize how a 
nascent management concept 
(VBHC) is diffused and 
understood in the health care 
literature 
25% of the citing articles 
demonstrated no 
understanding of VBHC; 
50% demonstrated a 
superficial understanding 
VBHC may be undergoing a 
process of dilution rather than 
diffusion. 
II. To test the hypothesis that 
implementing a patient-
initiated system of care could 
improve clinical outcomes for 
RA 
No significant differences in 
disease activity, satisfaction, 
confidence in care, or number 
of appointments  
Patient-initiated care was not 
better than traditional care in 
terms of outcomes analyzed. 
III. To test the 3-tier model 
against patients’ views of 
value in a chronic care setting 
The 3-tier model lacks 
dimensions of information, 
social health, predictability, 
and continuity. 
With modifications, the 
model is applicable to RA for 
research, clinical 
management, and outcome 
development. 
IV. To explore how persons 
with RA experience the use 
of the HAQ in care 
Persons with RA experience 
limitations of individual 
items, search for meaning in a 
partly faulty summative 
score, and wrestle with the 
effects of using HAQ. 
HAQ adds perceived value to 
clinical care, but needs either 
revising with patients or 
individualized prioritization 
among items. 
Note: VBHC = value-based health care; RA = rheumatoid arthritis; HAQ = health assessment questionnaire 
 
 
The studies outlined in Table 5 mainly correspond to the specific assumptions detailed 
earlier; however, the studies’ exploratory aspects make several substudies relevant to each 
assessed VBHC assumption. The substudies, therefore, are below presented thematically, 
with Sections 4.2 to 4.4 in correspondence with the respective assumptions. 
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4.1 VBHC IS NOT EMPIRICALLY ASSESSED IN THE LITERATURE 
Value is the most commonly referenced concept of VBHC. Of the articles that addressed 
Porter’s most cited article, 51% referred to the concept of value. The proportion of articles 
referring to different aspects did not change significantly over time. Commonly, the concepts 
of value were understood at a SOLO level between no idea and many ideas, with many ideas 
being most common (I). 
However, at the time of the assessment of the most cited article, there had been no empirical 
evaluation of the assumptions or theoretical development, and only five empirical 
applications. There was no longitudinal change of this trend in the literature (I).  
4.2 NON-OUTCOMES CAN HAVE INTRINSIC VALUE TO PERSONS WITH RA 
This section concerns the assumption, “Outcomes and only outcomes have intrinsic value to 
patients.” 
Outcomes was the best-understood concept in articles stating VBHC trends (I). Specifically, 
23% of the articles used the concept of outcomes when citing VBHC. Most authors were able 
to relate this concept to other concepts (Mdn = many ideas; IQR = one idea to relate). Studies 
that misunderstood outcomes (no idea), for example, confused it with patient-reported 
experience measures. 
In the interviews, outcomes had relevance to patients. When asked about what they valued, 
persons with RA overwhelmingly referred to outcomes (III). Sometimes, HAQ was even 
used as a tool to achieve a specific outcome (IV). The HAQ reporting was a way of 
communicating to the physician that a certain outcome was important to the participant. In 
addition, others expressed the value of aspects such as continuity, attitude of health care 
personnel, and time to diagnosis. 
Implementing a patient-initiated system of care did not demonstrate improvement in 
processes or outcome. The primary outcome, DAS28 (Figure 5) showed no significant 
differences over 18 months (p > 0.050). With a 95% confidence interval, the difference 
was -0.01 to 0.91 at 18 months. The HAQ, patient satisfaction, and confidence in care 
showed no significant difference throughout the trial or between groups (II). 
32 
  
Figure 5. Mean DAS28 in Intervention Group In relation to control, with 95% confidence 
interval. A positive value corresponds to the intervention group having higher DAS28, 
meaning higher disease activity. Scores were calculated with mixed model analysis adjusted 
for sex, disease onset, and age. Black numbers represent DAS28 means at measurement 
points.  
 
 
4.3 OUTCOMES NOT IN THE THREE-TIER MODEL CAN HAVE INTRINSIC 
VALUE TO PERSONS WITH RA 
This section concerns the assumption, “Outcomes important to patients can be subsumed 
under the three-tier model.” 
Outcomes important to persons with RA include all aspects of the three-tier model, apart 
from “Need for emergency department visits or hospitalizations” (III). When the outcome 
HAQ was used in care, it was sometimes seen as a way to bring the intricacies and 
complexity of life together into one holistic assessment (IV). However, participants differed 
markedly on which specific outcomes they valued. For example, some valued survival 
highly, while others emphasized function—explicitly disregarding survival.  
The same person could change the most important aspects between situations. For example, 
when seeking care for acute problems such as swollen joints, time to health status achieved 
would be most important; whereas when seeking care for chronic ailments, sustainable 
function, continuity, and attitude of health care personnel rose in importance. Reducing time 
spent accessing treatment became particularly important if an appointment had no 
consequence for the treatment (III). The RCT’s exploratory analysis showed that 
appointments in the intervention group more often resulted in a change in treatment 
(p < 0.001) (II). 
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Several outcomes not covered by the VBHC outcome model were important to participants 
(III). They valued feeling sufficiently informed, social support from family and health care, 
and predictability of disease. Information was important to accept the disease, mitigate long-
lasting questions, and enable self-care or self-control. In terms of social support as an 
outcome, participants made no distinction between support from family and support from 
health care. Predictability of disease was important to enable planning everyday life—
sometimes it was given more importance than low disease activity.  
The VBHC outcome model can be adjusted to better reflect outcomes in relation to the 
perspectives of persons with RA (III). Participants experienced different outcomes as 
important at different time points in their care process. The outcomes did not have 
hierarchical importance common to all. Further, some participants saw the most important 
outcome as being cured, even though there is no known cure for RA. Figure 6 illustrates the 
three-tier model from the perspective of persons with RA. 
Figure 6. Simplified Version of Outcome Model Developed in Substudy III Illustrates 
outcomes relevant from the perspective of persons with RA. “Cured” is included in the model 
because it would be highly valued by participants, even though there is (at present) no cure 
for RA. 
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4.4 HAQ DOES NOT ALIGN WITH THE PERSPECTIVE OF PERSONS WITH RA 
This section concerns the assumption, “Standardized outcome instruments measure outcomes 
that matter to patients.” 
The HAQ did not capture relevant functional aspects for persons with RA (IV). Participants 
experienced the instrument as useful and practical but did not think it measured all functional 
domains important to them. The instrument was important because of the effects it had on 
care and health perceptions. The three themes and their respective subthemes are outlined in 
Table 6. Participants reported problems concerned interpreting items, wanting to add new 
aspects of function, or wanting to remove “unimportant” items (i.e., items they found 
unnecessary or static). That is, the items either never applied to them or became irrelevant 
because they were used multiple times. 
 
 
Table 6. HAQ Experience for Persons with RA 
 Theme 
 Problem with 
Individual Items 
Meaning of Summative 
Score 
Effects on Care and 
Health Perceptions 
Subtheme:    
 Missing  Capturing holistic 
perspectives 
Effects on physician 
behavior 
 Unclear  Reflecting a temporary 
state 
Effects on understanding 
RA 
 Unnecessary  Requiring strategies for 
interpretation 
 
 Static    
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 5 DISCUSSION 
In summary, VBHC had been applied but not tested as of May 2014 (date of substudy I) with 
any longitudinal change. Further, in the rheumatology setting, the assessed assumptions did 
not find support. The substudies indicated that non-outcomes can have intrinsic value to 
persons with RA, and outcomes on the three-tier model level and on an instrument level of 
HAQ did not necessarily align with the perspectives of persons with RA.  
5.1 INTERPRETATIONS OF THE FINDINGS 
This section addresses three ways to consider the disagreement between the assumptions of 
VBHC and the findings in rheumatology: first, as determined by the VBHC stakeholder 
perspective; second, whether the discrepancy can be explained by how “outcome” is defined; 
and third, if the findings indicate lack of VBHC progression or pseudoinnovation.  
5.1.1 How well does VBHC acknowledge patient perspective? 
The developers of VBHC did not explicitly describe their method, and little evidence 
indicated it was made by or informed by patients. In response, a refined three-tier model 
suggested from patient interviews (Figure 6) highlights the feedback loop (dotted line in the 
original three-tier model of Figure 4) and removes the hierarchical aspects. The change better 
acknowledges that the outcomes important at the onset of disease are also important at 
recurrences. This is in line with Porter’s idea of the original model: “When recurrences or 
new illnesses occur, some higher-tier outcome dimensions such as survival, degree of 
recovery from the recurrence, and so on will also apply to measuring the outcome of these 
recurrences or illnesses” (38(p4)). The interview findings about value show that different 
aspects were important at different timepoints from the perspective of persons with RA. From 
a provider perspective, different priorities at different timepoints in the care cycle might be 
less obvious because providers treat patients at different stages of the care cycle 
simultaneously and thus measure all outcomes in parallel. 
Lately, studies in non-chronic care settings also tried to integrate the three-tier model with the 
patient perspective. Similar to the findings of this thesis (III), a study recognized the 
importance of the “time burden on patient and caregivers, and travel burden for patient and 
caregivers”(142). They also identified patient-provider communication as valuable, but the 
participating patients saw it as a driver of outcome rather than as an outcome itself. 
Correspondingly, participants in this thesis research ranked “attitude of staff” and 
“communication with staff” secondary to “time to health status achieved” if symptoms were 
non-chronic (III). However, patients considered these items valuable as an outcome when 
their symptoms were chronic. 
The aspects found important in this thesis (III) include continuity, information, and cure. 
Those aspects were also included in a recently developed, expanded value definition for 
primary care (143). This expanded definition encompasses health and “healing” (i.e., health 
status achieved) as seen in Porter’s three-tier model, but also includes cure and experience of 
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care (143). Experience of care aligns with the categories of continuity and information from 
the interviews in this thesis (III). In addition, the new definition addresses preconditions 
support—that is, factors facilitating everyday life such as social care (143). This support was 
not seen in the analysis of the three-tier model (III). However, when the interviews were 
analyzed in relation to HAQ (IV), a related finding surfaced about how problems can be 
solved in different ways—and “achieving the result on your own” was not always the 
patients’ top priority. For example, the valued outcome was not necessarily “being able to 
buy groceries,” but “to get groceries.” That is, going to the store would not be important 
(especially with assistance), but obtaining food would be. This prioritization aligns with the 
intention of VBHC. The existence of preconditions support such as social care would merely 
be a structural or process measurement and a means of achieving the true end (i.e., the 
outcome). 
Obviously, alignment with patient perspective is important to a framework that claims to 
focus on what really matters to patients. However, VBHC was not created primarily to 
increase patient influence or participation. Instead, its purpose was to solve the “cost crisis” 
and lack of quality improvement in health care (4). This thesis does not address those aspects 
of VBHC. Porter, originally a competition researcher (144) specializing in strategy, naturally 
addressed health care as an industry (145) from the provider (and payer) perspective. This can 
be counterintuitive because traditionally, public organizations focus more on cooperation than 
competition (146) and not all market principles apply to health care (147). However, a 
strategic approach could provide important insight, even though it affects the focus of VBHC. 
To illustrate this provider focus, Porter wrote, “Patient use [of outcomes] is secondary. The 
most important benefits of outcome measures are improved value in care delivery and 
information for referrals to other providers” (6). He argued that consumers (i.e., patients) 
could not use outcome information efficiently and instead medical teams would create 
improvements based on outcomes (12). In further examples, prevention has a peripheral role 
despite reasonably being the most cost-effective way to improve outcomes; in terms of 
experience, the focus is on provider experience rather than patient experience; self-care has 
no place in the framework (to date); the costs addressed concern only provider costs and not, 
for example, patient fees or patients’ lost working time; and so forth. 
In addition, the lack of alignment can also be seen in HAQ, the instrument studied in this 
thesis (IV). The findings show that applying readymade instruments does not guarantee 
measuring patient-perceived value (i.e., face validity in the care context). The instrument can 
still be valuable for other purposes such as research, but validity in research does not 
necessarily imply validity in care. In addition, instruments in research are analyzed on an 
aggregated level, whereas outcome instruments for care are used for individual patients. 
Porter previously argued that the instruments can be changed along the way, as long as 
organizations established the habits of learning and improvement (4(p136), 12). However, it 
is difficult to imagine by what mechanisms professionals are supposed to discover that the 
instruments they used for so long lacked relevance to patients. On the contrary, if the 
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 instruments were used extensively in research without professionals evaluating the value to 
patients, then it would be doubtful this would change because the instrument was also 
introduced in care. In addition, the more data collected with an instrument, the greater 
advantage the instrument will have in terms of historical and international comparability. This 
thesis does not address any setting other than rheumatology, and then only one instrument in 
rheumatology. However, considering this counter example, one cannot assume alignment 
between instruments and the patient perspective. It would be reasonable to conclude that 
showing agreement between patient perceptions and outcomes on a model level (that is, 
illustrating contextual relevance of the three-tier model) is not sufficient evidence to build 
VBHC. Agreement with the patient perspective should be shown also on an instrument level. 
Alignment of the patient perspective and outcomes measured could also have consequences 
for the motivation of professionals. Porter asserted that measuring outcome makes work more 
meaningful to professionals because they see the improvement they create for the patients. 
This might be the case, but it requires measuring outcomes important to patients, and not only 
those endorsed by professionals. An implementation study in Sweden showed a risk that 
professionals understand VBHC as measuring what they think patients should value (148). 
Professionals’ motivation to improve outcomes can be considered less important when they 
are not motivated by outcomes with actual value to patients. 
5.1.2 Are only outcomes important to persons with RA? 
Donabedian’s idea of sectioning data into structure, process, and outcomes (28) had a deep 
impact on management research. With its profound focus on outcomes, VBHC argues that 
structure and process are of importance only if they lead to improvement in outcomes. The 
RCT in the present thesis showed that a structural change of value to patients did not 
correspond to an improvement in outcome. Neither secondary outcomes nor patient 
satisfaction showed improvement. However, specific instruments to measure patient 
participation, such as patient activation measure (149) were not used during the trial. 
Although change in patient activation could be seen as an outcome or “result” of care, 
changing the system to patient-initiated care is not an outcome. It is a structural aspect. 
Similarly, aspects valuable in the interviews (continuity and attitude of health care personnel) 
(III) are traditionally considered process measures (150, 151). In the substudy, the argument 
was made that these aspects in themselves had such a profound effect on participants’ 
everyday life, they should be considered outcomes for chronic diseases. For example, lack of 
continuity would bother the participants beyond being a mechanism for worry or anxiety. 
With the same line of argument then, does this imply even patient initiation could be seen as 
an outcome due to its potentially profound importance in everyday life?  
The interview data do not show this result and reasonably, if this were the case, the profound 
effect would be the outcome not the patient initiation. However, this approach to redefining 
outcome means making the three-tier model, by definition, applicable to everything patients 
value. Indeed, as Porter asserted, the specific dimensions in the three-tier model were not 
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intended to be exhaustive (38). Nevertheless, it raises the question whether it is useful (152) 
to protect the core hypothesis (76) by adding auxiliary hypotheses (e.g., the additional 
hypothesis “continuity is an outcome in RA” protects “only outcomes are valuable”). Perhaps 
the data in the present thesis would be better represented by rejecting the assumption that 
persons with RA value only outcomes. 
In contrast to VBHC, the co-creation framework provides an alternative perspective on 
outcomes. In this framework, the co-creation experiences of individuals—their experiences of 
the process or of the outcome—determine value (25(p32)). This would mean that value also 
entails organizational improvement and personal, economic, or societal gains that are not 
limited to optimizing health outcomes (153). 
In addition, if one instead accepts the assumption that only outcomes have importance, the 
wide confidence interval in the RCT (II) and the (perhaps consequent) lack of effect 
illustrates how difficult managing based on outcomes can be in practice. Measuring impact 
on outcomes requires big data materials. The failure to show statistical impact parallels 
Donabedian’s assertion that relying solely on outcomes is not practical in the management of 
everyday care (35). 
5.1.3 Is VBHC a progressive research program? 
The lack of development, empirical tests, or critical application of the framework means 
VBHC is not currently advancing its position in relation to other strategic frameworks for 
health care. The empirical consequences of VBHC (i.e., predictions made by assumptions 
when formulating the specific aims) do not correspond to empirical findings in RA for the 
assumptions studied in this thesis. Considering that VBHC targets a generally evidence-based 
arena (i.e., health care), this section discusses what these findings and the current literature 
suggest for VBHC’s scientific status. 
Using Lakatos’ terminology (Section 3.1), this thesis could not show that VBHC is a 
progressive research program. Progressiveness, according to Lakatos, is the criterion that 
distinguishes science from pseudoscience. Does this mean VBHC is pseudoscientific? This 
thesis has not assessed all predictions made by VBHC; it has only showed that no other 
academic work has assessed prediction, and the thesis itself has failed to find support for 
predictions based on three critical assumptions of VBHC. In addition, progressiveness itself 
is not important, but how progressive the program is relative to competing programs. 
Certainly other programs, such as the broader quality improvement in health care, have seen 
progression and critical application (154), but other solutions with complexity similar to 
VBHC, such as Lean or TQM, have also seen degenerating popularity (15). The assessment 
of which is the “most progressive” program is therefore not obvious. 
5.1.3.1 Developments in VBHC after the research project start 
The trend in the VBHC literature (I) suggested VBHC would see no development in the 
upcoming years. However, a few developments of VBHC have been suggested recently, 
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 some of which were discussed above in relation to the patient perspective. In addition, one 
theoretical analysis suggested measuring different aspects on a population level rather than on 
an individual level—to measure chronic diseases with an emphasis on disease severity on the 
population level and patient experience on an individual level (155). Another study based on 
empirical data suggested developing VBHC by merging it with operational concepts. The 
purpose was to develop an instrument to assess changes when implementing VBHC (156). 
Their operationalization addresses all VBHC substrategies except spreading services 
geographically. As the only empirical study outside of this thesis (to the author’s best 
knowledge) that sought to develop VBHC, the discussion and an empirically founded 
development of VBHC were most welcome.  
However, despite the few recent suggestions, an argument could also be made that a lack of 
progression might be necessary in VBHC’s early stages—an argument that aligns with the 
position of the VBHC publications. Porter argued that we need to pass beyond the current 
focus on process measurements as soon as possible (9). The finding that participants in the 
present studies care primarily about outcomes (III) supports Porter’s argument. However, the 
relatively low use of outcomes compared with other measurements does not represent what 
patients value (e.g., among indicators in National Quality Measures Clearinghouse, only 8% 
were outcomes (157)). In line with this argument, it would be reasonable to accept lack of 
progression because testing the theory would result in lost implementation momentum. That 
is, because it is so important to measure outcomes, there is no time to improve the theory, test 
the framework, or think critically about the details. Despite the focus on criticism in this 
thesis, the interviews (III to IV) found support for measuring outcomes. In addition, early 
research programs require time to establish themselves (76). That is, VBHC requires patience 
towards its progressiveness—considering it was launched in 2006 (4). Although development 
of the theory is less visible, it seems applications are at full scale. The next paragraphs 
summarize recent applications. 
5.1.3.2 Applications of VBHC after project start 
Application of VBHC has mainly concerned developing outcome scorecards. Longitudinal 
invariance in understanding of the most-cited article led to the conclusion that the VBHC 
concepts would continue to be misused. Since the time of the review of articles citing the 
most-cited VBHC article (I), value and outcomes continue to be used improperly. For 
example, studies did not collect data on any outcome mentioned in the most-cited article 
(158), use a unidimensional outcome in relation to costs (159), or consider adherence to 
medicine as an outcome (155). Others confused clinical measurements with outcomes (160). 
In addition, an implementation study of VBHC in Sweden showed misunderstandings of 
VBHC among managers (148) similar to the ones seen in the literature. 
However, outcome scorecards that align with the three-tier model have also been developed 
with extensive patient participation (e.g., head and neck cancer (161) or breast cancer (32)) or 
without patients (e.g., in vascular surgery (162), bacteremia (163), spinal surgery (164), 
Parkinson’s disease (164), and thyroid cancer (165)). Interestingly, Fayanju et. al noted that 
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patients who were asked for outcomes named what the authors called “non-outcome entities,” 
such as “experts” or “CT scan.” That is, when asked for outcomes, patients named entities the 
three- tier model does not consider outcomes. However, because the authors used the three-
tier model rigidly, the studies discarded these results as not applicable to the model. Hence, 
those results were not included in their study findings (32). In contrast, the present thesis 
study instead criticized the three-tier model (III) when it did not agree with the patient 
perspective. 
The nongovernmental organization, International Consortium for Health Outcomes 
Measurement, has facilitated several outcome scorecards for VBHC. However, the scorecards 
they published thus far were not separated on the three-tier model tiers. In addition, the 
scorecards prioritized scientifically rigorousness with an emphasis on standardized 
instruments rather than patient perceived value. So far, they have included only one to three 
patient-participants in a much bigger committee of professionals (e.g., 166-169). 
Nevertheless, their outcomes have already been employed in care evaluation (e.g., for 
prostate brachytherapy (170, 171)). 
These implementations and the argument preceding them suggest there is a disproportion 
between critical assessment of VBHC and the extent of implementations. Progressiveness, 
according to Lakatos, concerns whether changes of VBHC lead to predictions that are more 
accurate. From this follows that in order to be progressive and hence scientific, the research 
program must be ready to revise itself. Obviously, scientific theories are preferable in health 
care. Even though the literature citing VBHC showed no trend in testing or developing 
VBHC (I), there is still time for VBHC to pursue progressiveness.  
5.1.4 Is VBHC a pseudoinnovation? 
Leaving the rather abstract question of VBHC’s scientific status for a more empirical 
analysis, the disproportion of implementation and critique suggests an uncritical 
implementation of VBHC. This characterizes pseudoinnovation (17). Implementation of 
pseudoinnovations generates small technical benefits to the system; therefore, uncovering 
pseudoinnovations is important (20). There are no fixed criteria for categorizing innovations 
as pseudoinnovative (15). This section will therefore only address aspects indicating that 
VBHC is a pseudoinnovation. 
Although the literature on VBHC refrained from positioning itself in relation to other 
strategic health care frameworks, several striking similarities with earlier research literature 
emerged in the background chapter. For example, similarity exists between Fries’ 1983 
outcome model (Figure 1) and Porter’s 2010 three-tier model (Figure 1), as well as the value 
equation (Section 1.3.2) to the cost-effectiveness analysis of classical health economy 
(Section 1.3.1). 
However, one could argue that the differences constitute improvements in making the models 
more practically relevant or easier to apply in daily clinical practice and health care 
governance as opposed to the other frameworks used more often in research. Instances 
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 include the decision to separate costs from outcomes and highlight the relationship between 
them, or the much more intuitive and practical equation of outcomes/cost compared to the 
policy-centered and abstract equation, cost-effectiveness = cost/outcomes. Nevertheless, other 
VBHC concepts are largely the same as ‘competing’ concepts. For example, the concept of 
cycle of care is similar to clinical pathways (172) and value stream in Lean. If small 
differences make the framework more practical than its alternatives, then this implies the 
focus should be on these differences in order to bring innovation through VBHC in 
implementation. 
5.2 A NEW SUBSTRATGY MOVING FORWARD?  
The critique of VBHC in this thesis concerned relevance of the outcomes to the patients and 
progressiveness of VBHC. Because patients are the only source used for assessment of 
VBHC assumptions in this thesis—and simultaneously the target of most health care 
development—the critique can be subverted by including patients in VBHC implementation. 
Perhaps it would be reasonable to add a seventh substrategy to the ones described in section 
1.3.2.3: “New measurements (and care processes) should be developed in partnership with 
patients.” There is no theoretical conflict between working in partnership with patients and 
working with VBHC. However, it could be that patient perspectives and VBHC assumptions 
do not agree in practice, as seen in the RA setting in this thesis. This suggests that if 
partnership was included as a substrategy, there would be trade-offs between the substrategies 
(e.g., patient perceived value and measurement of outcomes). Although adding this 
substrategy eliminates the critique of this thesis, the feasibility of this seventh substrategy is, 
like the feasibility of the other substrategies, a suggestion that needs empirical study.  
5.3 TRANSFERABILITY 
The substudy designs and findings closely tie to patient perspectives characteristic in chronic 
care settings. Patient initiation of care (II) requires, among other things, that patients are able 
to notice when they should seek care and have had the medical condition for a sufficiently 
long time to learn the characteristics of their disease. In RA, a disease flare is noticeable to 
the patient; other chronic conditions (such as diabetes or high blood pressure) require medical 
equipment for patients to judge their disease status. Further, acute diseases might be difficult 
to arrange with patient initiation in a safe manner because recognizing a flare might require 
experience. In addition, the interviews highlight continuity, attitude of health care personnel 
(III), understanding the meaning of HAQ, and the value of holistic assessment (IV). Those 
aspects might be more important in chronic diseases compared to acute episodes because 
chronic diseases have a greater need for coordination and complex interventions (51). 
Further, the emphasis put on life quality over life expectancy (III) can also be seen in other 
incurable diseases (173). However, the patients’ rich opinions about HAQ seemed to be 
affected by longitudinal involvement with the measurement and its impact on care. The 
influence of measurements is prevalent in the Swedish rheumatology setting (105), but it is 
(currently) rare in other settings. Swedish registry based data collection is supported by high 
degree of generalized trust, unique personal identification numbers and publicly funded 
43 
health care (174). For this reason, Swedish rheumatology was suitable for the aim of this 
thesis, but transferring the findings to other settings could be considerably difficult. 
5.4 STRENGTHS AND LIMITATIONS 
This thesis tackles VBHC from several methodological stances. Specific methods were 
chosen based on their applicability to specific aims, and multiple methods were only used in 
Substudy I. The general limitations of the specific methods are mitigated by several 
approaches (i.e., intermethod reliability (42) or methodological triangulation (43)). However, 
the findings from the interviews are affected by the chosen method. That is, analyses of 
qualitative data aim for depth but reduce attainable breadth. Although depth was the purpose 
of the interviews, an exploratory mixed-methods design (where the interview results are used 
to construct a survey) would have generated greater generalizability. Similarly, the substudy 
evaluating the three-tier model (III) compared the results with qualitative studies. However, 
quantitative studies of relevance to the three-tier model were not addressed (eg. 175). Even 
though comparing qualitative findings with quantitative studies can be very challenging, it 
likely would have generated additional insights. 
In tackling VBHC assumptions rather than implementation, different knowledge was gained. 
The overarching question of whether VBHC works as intended is empirical and could best be 
answered by studying the consequences of implementing VBHC. Such a study was not 
included in the present thesis, primarily because data on controlled implementations or access 
to multiple cases for cross-case analysis is rare. Further, such implementations in Sweden 
would hardly be transferable to other settings at present, considering the advantages the 
Swedish setting has in implementing VBHC (118). Instead, assessing the assumptions—as in 
this thesis—is more feasible. Further, such assessment provides knowledge of the 
mechanisms of the theory and may give insight into flaws that would not become obvious in 
a noisy empirical case study. As such, the theoretical assessment complements an 
implementation study. In conjunction with this assertion, the setting of rheumatology serves 
as a setting for all the assessments made, although multiple settings would have provided 
greater transferability or generalizability. For this reason, one must be careful about 
transferring any of the findings to other medical conditions or to non-Swedish settings. In 
addition, this thesis does not fully cover the rheumatology setting or even RA. For example, 
this thesis does not address instruments commonly used for outcome assessment in RA (other 
than HAQ). However, the purpose of this thesis did not aim to adjust VBHC to the RA 
setting, but rather to show how assumptions made by the theory are not universally true. 
Although previous studies criticized VBHC for lacking patient centeredness (54), no study 
systematically assessed VBHC in relation to the patient perspective as extensively as this 
thesis. This study covers only outcomes in VBHC but is, to date, the most comprehensive 
assessment of VBHC in relation to the patient perspective. The RCT and interview studies 
(II to IV) of this thesis were informed by, not coproduced with, patients. Critical theory 
argues that it is not enough to ask participants, because their perspectives would be framed by 
the researcher-chosen methods and questions (135). A full partnership with patients is seen 
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 as the best way to mitigate this risk. Although this thesis was not designed from the 
perspective of critical theory, the criticism still holds. 
The outcome used in the RCT—DAS28—is the most commonly used global assessment 
outcome in RA trials (73) but has not been confirmed to be valuable to patients (129). The 
RCT showed no improvement in HAQ either, but as demonstrated from the interviews (IV), 
HAQ does not capture functional aspects of value. When this thesis assessed the assumptions, 
it assumed they were independent. This means that the substudies designed to assess the 
assumptions assumed the other VBHC assumptions are true. When the studies were designed, 
it was not known that the assumptions would not find support. This approach neglects any 
interaction effects and means the substudies results are not connected to only one specific 
assumption. The lack of effect on outcomes in the RCT could also be explained by the fact 
that the outcomes measures were not in fact outcomes valuable to patients. This implies that 
the intervention actually may have improved outcomes after all, but the right outcomes were 
not measured. In retrospect, it is difficult to suggest what would have been a suitable primary 
outcome for the RCT, as the commonly used outcome measures, DAS28 and HAQ, are not 
valuable to persons with RA. The EuroQol five dimensions questionnaire, measured in 
Swedish rheumatology and among the instruments suggested by Porter, was not studied in 
this thesis. However, a review from 2013 suggested patient reported health related quality of 
life is not affected by patient-initiated appointments (70). 
The findings in the RCT (II) did not fulfill the criterion of non-inferiority analyses (176). The 
substudy conclusion (i.e., that the intervention is as safe as standard care) is based on lack of 
significant difference in DAS28. However, the risk of false negative when assessing only the 
p-value is 20%, because it corresponds to the statistical power of 80%. The 5% significance 
level only determines the risk of false positives. This is relevant because the significance level 
required to implement an intervention is usually p < 5%. Instead, under the principles of a 
non-inferiority analysis (176), the p-value is disregarded in favor of the 95% confidence 
interval. In the RCT, the confidence interval was -0.01 to 0.91. This entails both 0.0 and 0.6 
(least clinically significant effect of DAS28 in RA), which means the study sample is not 
large enough to conclude that patient-initiated care was not inferior to standard care. It only 
demonstrates that it was not better than standard care. Despite this limitation, the substudy 
still supports the argument made in this thesis concerning the assumption assessed, because 
the purpose of this thesis was only to show that patient-initiated appointments were not 
superior in outcomes.  
A parallel qualitative analysis of the RCT intervention would help understand the underlying 
mechanism of the intervention. Based on the data from the RCT, it was difficult to explain 
why it did not demonstrate effects on DAS28. A concurrent qualitative study employing 
observations or interviews might have rendered explanatory data on the mechanisms active 
during the RCT. 
To develop the three-tier model (III), an approach closer to grounded theory (177) would 
have been more applicable than was content analysis. A grounded theory approach could 
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have led to a more elaborate development of the hypotheses that emerged late in the analysis 
process (e.g., time spent on self-care as a consequence of care, and whether time spent 
accessing treatment should be moved to consequences of care or included in both time to 
health and consequences of care). The interview guide was developed iteratively, and the first 
six interviews completely analyzed before subsequent interviews were performed. However, 
as saturation was reached, the deeper analysis (and re-analysis of interviews) was not 
conducted until all the data were collected. A fully iterative approach and iterative model 
development might have been more suitable. However, “by-the-book” grounded theory (177) 
is not suitable to model evaluation because grounded theory strives to build a model without 
preconceived ideas. 
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6 CONCLUSION 
This thesis shows potential limitations concerning assumptions about outcomes made by 
VBHC in an RA setting and simultaneously illustrates sparse empirical development of 
VBHC. In RA, aspects other than outcomes can be important, the three-tier model does not 
address all important outcomes, and instruments are not necessarily aligned with important 
aspects of outcomes. Although the empirical evidence in this thesis is not sufficient to suggest 
specific adjustments to VBHC, it is obvious more research should precede full-scale VBHC 
implementation. Researchers seeking to develop VBHC could start with the assumptions 
assessed in this thesis because these areas seem to lack alignment between what VBHC 
assumes and what persons with RA value. Further, studies of assumptions not assessed in this 
thesis and consequences of implementations are warranted. 
The criticism of VBHC in this thesis concerns outcomes in relation to the patient perspective 
(using RA as a model for chronic disease). This means the criticism would fall if VBHC were 
implemented in partnership with patients and with a willingness to change aspects of VBHC 
based on the patient assessments. Such a change would correspond to adding a seventh 
substrategy to the six described by VBHC: “New measurements (and care processes) should 
be developed in partnership with patients.” 
6.1 IMPLICATIONS 
6.1.1 For patients 
Outcomes of VBHC are not aligned with what persons with RA perceive as valuable. This 
might be the case for other chronic medical conditions as well. Patients have reason to assess 
outcomes suggested by VBHC critically, asking themselves, “Is this really valuable to me?”  
6.1.2 For policy makers and managers 
The VBHC is often misunderstood and lacks empirical evidence. Any implementation should 
be carefully studied and performed in partnership with patients. Large-scale implementations 
should be avoided until more evidence is gathered.   
6.1.3 For healthcare professionals 
Outcomes currently used in care might not be relevant in improving value as perceived by 
patients. In the RA setting, continuity of care and attitude towards patients are still important, 
contrary to what VBHC asserts. This might be the case for other chronic diseases as well. 
6.1.4 For outcome researchers 
Instruments developed for research might not be relevant to patients for use as outcomes in 
care. Achieving relevance requires assessment of standardized instruments and, if necessary, 
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development of new instruments together with patients. Many medical conditions lack 
outcomes known to be important to patients. 
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